US 6114376 A - Methods For Using Macrocyclic Lactone Compounds As Multidrug Resistance Reversing Agents In Tumor And Other Cells - The Lens

Methods For Using Macrocyclic Lactone Compounds As Multidrug Resistance Reversing Agents In Tumor And Other Cells

Published: Sep 5, 2000
Earliest Priority: Apr 30 1997
Family: 14
Cited Works: 6
Cited by: 31
Cites: 10
Additional Info: Cited Works Full text Published

Abstract

This invention describes methods for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against resistant tumor cells in mammals which comprise administering a multidrug resistant reversing agent to the mammal in connection with the administration of the cytostatic hydrophobic chemotherapeutic agent in an amount effective to increase the toxicity of the chemotherapeutic agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound. Examples of the macrocyclic lactone compounds useful in the present invention include, but are not limited to, the LL-F28249 alpha - lambda series of compounds, the 23-oxo or 23-imino derivative thereof, the avermectins, the 22,23-dihydro derivatives thereof and the milbemycins. Compositions comprising the macrocyclic lactone compounds and the chemotherapeutic agents are also described herein.

Claims

A method for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against a resistant tumor cell in a mammal which comprises administering a multidrug resistant reversing agent to the mammal in connection with administering the cytostatic hydrophobic chemotherapeutic agent in an amount effective to increase the toxicity of the chemotherapeutic agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound selected from the group consisting of LL-F28249α-λ, a 23-oxo derivative of LL-F28249α-λ, a 23-imino derivative of LL-F28249α-λ, an avermectin, a 22,23-dihydro derivative of avermectin and a milbemycin.
The method according to claim 1, wherein the macrocyclic lactone compound is administered orally, parenterally, topically or transdermally.
The method according to claim 1, wherein the macrocyclic lactone compound is LL-F28249α, 23-(O-methyloxime)-LL-F28249α, 23-(semicarbazone)-LL-F28249α, 23-(thiosemicarbazone)-LL-F28249α, an isomeric mixture of (E) and (Z)-26-formyl-(O-methyloxime)-LL-F28249α, ivermectin, abamectin, doramectin, eprinomectin, milbemycin A or milbemycin D.
The method according to claim 1, wherein the chemotherapeutic agent is selected from the group consisting of vinblastine, vincristine, doxorubicin, paclitaxel, colchicine, actinomycin D and gramicidin D.
The method according to claim 1, wherein the mammal is selected from the group consisting of a human, a dog, a cat and a horse.
The method according to claim 1, wherein the resistant tumor cell is selected from the group consisting of a human lymphoma cell, a human breast cancer cell, a human ovarian cancer cell and a human lung cancer cell.
An improved method for treating a resistant tumor cell in a mammal which comprises administering to the mammal a tumor suppressing amount of a cytostatic hydrophobic chemotherapeutic agent and a multidrug resistant reversing agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound selected from the group consisting of LL-F28249α-λ, a 23-oxo derivative of LL-F28249α-λ, a 23-imino derivative of LL-F28249α-λ, an avermectin, a 22,23-dihydro derivative of avermectin and a milbemycin.
The method according to claim 2, wherein the macrocyclic lactone compound is administered before or concomitantly with the chemotherapeutic agent.
The method according to claim 7, wherein the macrocyclic lactone compound is administered orally, parenterally, topically or transdermally.
The method according to claim 7, wherein the macrocyclic lactone compound is LL-F28249α, 23-(O-methyloxime)-LL-F28249α, 23-(semicarbazone)-LL-F28249α, 23-(thiosemicarbazone)-LL-F28249α, an isomeric mixture of (E) and (Z)-26-formyl-(O-methyloxime)-LL-F28249α, ivermectin, abamectin, doramectin, eprinomectin, milbemycin A or milbemycin D.
The method according to claim 7, wherein the chemotherapeutic agent is selected from the group consisting of vinblastine, vincristine, doxorubicin, paclitaxel, colchicine, actinomycin D and gramicidin D.
The method according to claim 7, wherein the mammal is selected from the group consisting of a human, a dog, a cat and a horse.
The method according to claim 7, wherein the resistant tumor cell is selected from the group consisting of a human lymphoma cell, a human breast cancer cell, a human ovarian cancer cell and a human lung cancer cell.
An improved composition for treating a resistant tumor cell in a mammal which comprises a tumor suppressing amount of a cytostatic hydrophobic chemotherapeutic agent, a multidrug resistance reversing agent and a nontoxic pharmaceutically acceptable carrier, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound selected from the group consisting of LL-F28249α-λ, a 23-oxo derivative of LL-F28249α-λ, a 23-imino derivative of LL-F28249α-λ, an avermectin, a 22,23-dihydro derivative of avermectin and a milbemycin.
The composition according to claim 14, wherein the chemotherapeutic agent is selected from the group consisting of vinblastine, vincristine, doxorubicin, paclitaxel, colchicine, actinomycin D and gramicidin D.